Nitrogen-containing tricyclic compounds and their applications

By providing a compound of formula (I) or a pharmaceutically acceptable salt thereof, selective inhibition of JAK1 and/or JAK2 was achieved, overcoming the shortcomings of existing selective inhibitors of JAK family members in the treatment of JAK-related diseases, and demonstrating efficacy in vitro and in mice.

CN115403594BActive Publication Date: 2026-11-17CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210579297.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-26
Filing Date
2022-05-25
Publication Date
2026-11-17
Estimated Expiration
2042-05-25

AI Technical Summary

Technical Problem

Existing technologies have not yet effectively addressed the application of selective inhibitors of JAK family members in the treatment of JAK-related diseases, especially in the specific treatment of inflammatory conditions and other diseases driven by JAK-mediated signal transduction.

Method used

Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided for the preparation of medicaments for treating JAK-related diseases by selectively inhibiting JAK1 and/or JAK2 kinases.

Benefits of technology

It exhibits good selective inhibition of JAK1 and/or JAK2 in vitro and demonstrates good oral bioavailability and high exposure in mice, showing potential for the treatment of JAK-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115403594B_ABST
    Figure CN115403594B_ABST
Patent Text Reader

Abstract

This application relates to nitrogen-containing tricyclic compounds. Specifically, it relates to compounds of formula (I), their isomers or pharmaceutically acceptable salts thereof, and their use in the preparation of medicaments for treating JAK-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This disclosure claims the benefit and priority of Chinese Patent Application No. 202110580182.4, filed with the State Intellectual Property Office of the People's Republic of China on May 26, 2021, the entire contents of which are hereby incorporated herein by reference. Technical Field

[0003] This application relates to nitrogen-containing tricyclic compounds, specifically to compounds of formula (I), their isomers or pharmaceutically acceptable salts thereof, and their use in the preparation of medicaments for treating JAK-related diseases. Background Technology

[0004] Janus kinases (JAKs) are cytosine kinases that transmit cytokine signals from membrane receptors to STAT transcription factors. The JAK family comprises four members: JAK1, JAK2, JAK3, and TYK2. The JAK-STAT pathway transduces extracellular signals from a variety of cytokines, growth factors, and hormones to the nucleus and is responsible for the expression of thousands of protein-coding genes. Intracellular JAK-STAT signal transduction serves interferons, most interleukins, and a variety of cytokines and endocrine factors such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF, and PRL (Vainchenker WE T al. (2008)).

[0005] JAK-1, JAK-2, and TYK-2 are expressed in all human tissues and cells, while JAK-3 is mainly expressed in hematopoietic cells, primarily found in bone marrow cells, thymocytes, NK cells, and activated B and T lymphocytes. JAK1 has become a novel target for diseases such as immunity, inflammation, and cancer. A single base mutation in the JAK2 gene, JAK2V617F, is closely related to the development of myeloproliferative disorders such as polycythemia vera (PV), idiopathic thrombocythemia (ET), idiopathic myelofibrosis (IMF), and chronic myeloid leukemia (CML). JAK3 or γc mutations can lead to severe combined immunodeficiency. Abnormal JAK3 activity manifests as a significant reduction in T and NK cells and loss of B cell function, severely impacting the normal biological functions of the immune system. Based on its functional characteristics and specific tissue distribution, JAK3 has become a highly attractive drug target for immune system-related diseases. In mice, loss of TYK2 function leads to defects in signaling pathways of multiple cytokine receptors, resulting in viral infections, decreased antimicrobial immunity, and an increased likelihood of lung infections (John J. O'Shea, 2004, Nature Reviews Drug Discovery 3, 555-564). Different JAK family members selectively bind to different cytokine receptors, conferring signal transduction specificity and thus exerting different physiological effects. This selective mechanism of action allows JAK inhibitors to be applied relatively specifically to disease treatment. For example, IL-2 or IL-4 receptors, along with their shared γ chain, bind to JAK1 and JAK3, while type I receptors with the same β chain bind to JAK2. Type I receptors using gp130 (glycoprotein 130) and type I receptors activated by heterodimeric cytokines preferentially bind to JAK1 / 2 and TYK2. Type I receptors activated by hormone-like cytokines bind to and activate JAK2 kinase. Interferon type II receptors bind to JAK1 and TYK2, while receptors of the IL-10 cytokine family bind to both JAK1 / 2 and TYK2. The specific binding of these cytokines and their receptors to various JAK family members triggers diverse physiological effects, offering potential therapeutic possibilities for different diseases. Heterodimerization of JAK1 with other JAKs can transduce cytokine-driven pro-inflammatory signaling. Therefore, inhibition of JAK1 and / or other JAKs is expected to have therapeutic benefits for a range of inflammatory conditions and other diseases driven by JAK-mediated signal transduction (Daniella M. Schwartz, 2017, Nature Reviews Drug Discovery 16, 843-862). Summary of the Invention

[0006] This application provides a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0007]

[0008] in,

[0009] m is 1, 2, 3, 4 or 5;

[0010] n is 1, 2, 3 or 4;

[0011] Ring A is selected from C 3-6 cycloalkyl or 4-6 membered heterocyclic alkyl;

[0012] Each R 1 Each of the following is independently selected from H, F, Cl, Br, I, OH, NH2, CN, or C. 1-3 alkyl;

[0013] Each R 2 Each of the following is independently selected from H, F, Cl, Br, I, CN, OH, NH2, or C. 1-3 alkyl;

[0014] L is -(CR) a R b ) p -;

[0015] p is 0, 1, 2 or 3;

[0016] R a and R b Each of the following is independently selected from H, F, Cl, Br, I, OH, CN, or methyl.

[0017] In some embodiments, the heterocyclic alkyl group comprises 1, 2, 3 or 4 heteroatoms or heterogroups independently selected from -O-, -NH-, -S- or N.

[0018] In some embodiments, the heterocyclic alkyl group comprises 1, 2, 3 or 4 heteroatoms or heterogroups independently selected from -NH- or N.

[0019] In some embodiments, the heterocyclic alkyl group each comprises a single heteroatom or heterogroup selected from -NH- or N.

[0020] In some implementations, m is 1, 2, or 3. In some implementations, m is 1 or 2. In some implementations, m is 1.

[0021] In some implementations, n is 1, 2, or 3. In some implementations, n is 1 or 2. In some implementations, n is 1.

[0022] In some implementations, ring A is selected from C. 3-6Cycloalkyl or heterocyclic alkyl with 4-6 nitrogen atoms.

[0023] In some implementations, ring A is selected from C. 3-5 Cycloalkyl or 4-5 membered heterocyclic alkyl. In some embodiments, ring A is selected from C. 3-5 Cycloalkyl or 4-5 membered heterocyclic alkyl containing nitrogen atoms.

[0024] In some embodiments, ring A is selected from cyclopropyl, cyclobutyl, or heterocyclobutane.

[0025] In some implementation schemes, each R 1 Each is independently selected from H, OH, CN, or C. 1-3 alkyl.

[0026] In some implementation schemes, each R 1 Each is independently selected from H, OH, CN, or methyl.

[0027] In some implementations, n is 1 or 2, and each R 1 Each is independently selected from H, OH, CN, or methyl.

[0028] In some implementation schemes, each R 2 Each of the following is independently selected from H, F, Cl, Br, I, CN, OH, NH2, or methyl.

[0029] In some implementation schemes, each R 2 Each can be independently selected from H or CN.

[0030] In some implementations, m is 1, R 2 Selected from H, F, Cl, Br, I, CN, OH, NH2 or C 1-3 alkyl.

[0031] In some implementations, m is 1, R 2 Selected from H, F, Cl, Br, I, CN, OH, NH2 or methyl.

[0032] In some implementations, m is 1, R 2 For CN.

[0033] In some implementations, p is 0 or 1.

[0034] In some implementation schemes, R a Selected from H, R b Selected from H, F, Cl, Br, I, OH, CN or methyl.

[0035] In some implementation schemes, R a and R b Each is independently selected from H or OH.

[0036] In some implementation schemes, R a Selected from H, R b Selected from H or OH.

[0037] In some implementations, L is a bond, -CH2-, or -CH(OH)-.

[0038] In some implementation schemes, structural units Selected from

[0039] In some implementation schemes, structural units Selected from

[0040] In some implementation schemes, structural units Selected from

[0041] In some implementation schemes, structural units Selected from

[0042] In some implementation schemes, structural units Selected from

[0043] In some implementation schemes, structural units Selected from

[0044] In some embodiments, m is 1; n is 1 or 2; ring A is selected from cyclopropyl, cyclobutyl, or heterocyclobutane; each R 1 Each is independently selected from H, OH, CN, or methyl; R 2 CN; L represents a bond, -CH2- or -CH(OH)-.

[0045] In this application, there are also some implementation schemes that are derived from any combination of the above variables.

[0046] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is a compound of formula (I-1) or a compound of formula (I-2) or a pharmaceutically acceptable salt thereof.

[0047]

[0048] in,

[0049] Rings A and R 1 R 2 , n, m and L are as defined in this application.

[0050] In some embodiments, in the compound of formula (I-1) or formula (I-2), the structural unit The definition is as described above.

[0051] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is a compound of formula (II) or a pharmaceutically acceptable salt thereof.

[0052]

[0053] in,

[0054] Rings A and R 1 , n and L are as defined in this application.

[0055] In some embodiments, in the compound of formula (II), the structural unit The definition is as described above.

[0056] In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt thereof is a compound of formula (II-1) or a compound of formula (II-2) or a pharmaceutically acceptable salt thereof.

[0057]

[0058] in,

[0059] Rings A and R 1 , n and L are as defined in this application.

[0060] In some embodiments, in the compound of formula (II-1) or the compound of formula (II-2), the structural unit The definition is as described above.

[0061] The following compounds or their pharmaceutically acceptable salts:

[0062]

[0063] The following compounds or their pharmaceutically acceptable salts:

[0064]

[0065] Furthermore, this application also provides pharmaceutical compositions comprising the above-described compounds of this application or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions of this application further include pharmaceutically acceptable excipients.

[0066] In another aspect, this application also provides the use of the above-mentioned compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of JAK-related diseases.

[0067] In another aspect, this application also provides the use of the above-mentioned compounds or pharmaceutically acceptable salts thereof in medicaments for the treatment or prevention of JAK-related diseases.

[0068] In another aspect, this application also provides the above-mentioned compounds or pharmaceutically acceptable salts thereof for the treatment or prevention of JAK-related diseases.

[0069] On another aspect, this application also provides a method for treating or preventing JAK-related diseases, comprising administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a mammal, preferably a human, in the treatment of which the treatment is required.

[0070] In this application, the aforementioned JAK-related diseases are selected from JAK1 and / or JAK2-related diseases.

[0071] In this application, the aforementioned JAK1 and / or JAK2-related diseases are selected from inflammatory conditions (such as arthritis).

[0072] Technical effect

[0073] The compounds of this application exhibited good selective inhibition of JAK1 and / or JAK2 in in vitro kinase activity tests (such as JAK1, JAK2, JAK3 and TYK2); they also showed good oral bioavailability in mice, with high exposure levels that are conducive to producing good in vivo efficacy.

[0074] Definitions and Explanations

[0075] Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings. A particular term or phrase should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.

[0076] The term “pharmaceutically acceptable” as used herein refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.

[0077] The term "pharmaceutically acceptable salt" refers to the salt of the compounds in this application, prepared by reacting a compound with a relatively non-toxic acid or base, as discovered in this application, with a specific substituent. When the compounds in this application contain relatively acidic functional groups, base addition salts can be obtained by contacting such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts, or similar salts. When the compounds in this application contain relatively basic functional groups, acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanoic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; as well as salts of amino acids (such as arginine) and salts of organic acids such as glucuronic acid. Certain specific compounds of this application contain both basic and acidic functional groups, and thus can be converted into either a base or an acid addition salt.

[0078] The pharmaceutically acceptable salts of this application can be synthesized from parent compounds containing an acid radical or a base using conventional chemical methods. Generally, such salts are prepared by reacting these compounds, in their free acid or base form, with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of both.

[0079] The compounds of this application may exist in specific geometric or stereoisomeric forms. This application envisions all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this application. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this application.

[0080] Unless otherwise stated, the terms "enantiomer" or "optical isomer" refer to stereoisomers that are mirror images of each other.

[0081] Unless otherwise stated, the terms "cis-trans isomers" or "geometric isomers" arise because the single bonds of double bonds or cyclic carbon atoms cannot rotate freely.

[0082] Unless otherwise stated, the term "diastereomer" refers to a stereoisomer of a molecule having two or more chiral centers and being in a non-mirror relationship with each other.

[0083] Unless otherwise stated, "(+)" indicates right-handed rotation, "(-)" indicates left-handed rotation, and "(±)" indicates racemic rotation.

[0084] Unless otherwise specified, use wedge-shaped solid line keys ( ) and wedge-shaped dashed key ( The absolute configuration of a solid center is represented by a straight solid line key ( ). ) and straight dashed key ( The relative configuration of the center of a solid is represented by a wavy line. ) indicates a wedge-shaped solid line key ( ) or wedge-shaped dashed key ( ), or use wavy lines ( ) indicates a straight solid line key ( ) and straight dashed key ( ).

[0085] Unless otherwise stated, the terms "tautomer" or "tautomer form" refer to isomers with different functional groups in dynamic equilibrium at room temperature, capable of rapidly interconverting into each other. Tautomers can be chemically equilibrated if possible (e.g., in solution). For example, proton tautomers (also called prototropic tautomers) involve interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers involve interconversions involving the rearrangement of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between the tautomers pentane-2,4-dione and 4-hydroxypent-3-en-2-one.

[0086] Unless otherwise stated, the terms "rich in one isomer," "isomer enrichment," "rich in one enantiomer," or "enantiomer enrichment" mean that the content of one isomer or enantiomer is less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.

[0087] Unless otherwise stated, the terms "isomer excess" or "enantiomer excess" refer to the difference between the relative percentages of two isomers or two enantiomers. For example, if one isomer or enantiomer is 90% and the other isomer or enantiomer is 10%, then the isomer or enantiomer excess (ee value) is 80%.

[0088] Optically active (R)- and (S)- isomers, as well as D- and L- isomers, can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. To obtain an enantiomer of a compound of this application, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the desired enantiomer in pure form. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a salt of the diastereomeric isomer is formed with a suitable optically active acid or base, followed by diastereomeric resolution using conventional methods known in the art, and then the pure enantiomer is recovered. Furthermore, the separation of enantiomers and diastereomeric isomers is typically accomplished by using chromatography employing a chiral stationary phase and optionally combined with chemical derivatization (e.g., from amines to carbamates).

[0089] The compounds of this application may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compound may be labeled with radioactive isotopes, such as tritium. 3 H), Iodine-125 125 I) or C-14 14 C). For example, deuterium can be used to replace hydrogen to form deuterated drugs. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged drug biological half-life. All isotopic variations of the compounds in this application, regardless of radioactivity, are included within the scope of this application. "Optional" or "optionally" means that the events or conditions described below may occur but are not necessary, and the description includes both the occurrence and non-occurrence of said events or conditions.

[0090] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which can include deuterium and hydrogen variants, provided that the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that it may or may not be substituted, unless otherwise specified, and the type and number of substituents can be arbitrary on a chemically feasible basis.

[0091] When any variable (e.g., R) appears more than once in the composition or structure of a compound, its definition is independent in each case. Thus, for example, if a group is substituted by 0-2 Rs, the group can optionally be substituted by at most two Rs, and the Rs in each case have independent options. Furthermore, combinations of substituents and / or their variants are only permitted if such combinations produce a stable compound.

[0092] When one of the variables is selected as a single bond, it means that the two groups it connects to are directly connected. For example, when L in ALZ represents a single bond, it means that the structure is actually AZ.

[0093] When a substituent is vacant, it means that the substituent does not exist. For example, if X is vacant in AX, the structure is actually A. When the listed substituents do not specify which atom they are attached to the substituted group through, such substituents can be bonded to any of their atoms. For example, a pyridinium group as a substituent can be attached to the substituted group through any carbon atom on the pyridine ring.

[0094] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group. This alkyl group can be straight-chain or branched. For example, the term "C 1-6 "Alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio groups has the same definition as above.

[0095] Unless otherwise specified, C n-n+m Or C n -C n+m This includes any specific case with n to n+m carbons, such as C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 C 11 and C 12 It also includes any range from n to n+m, such as C 1-12 Including C 1-3 C 1-6 C 1-9 C 3-6 C 3-9 C 3-12 C 6-9 C 6-12 and C 9-12Similarly, n-membered to n+m-membered rings represent the number of atoms in the ring from n to n+m. For example, 3-12-membered rings include 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, and 12-membered rings, and also any range from n to n+m. For example, 3-12-membered rings include 3-6-membered, 3-9-membered, 5-6-membered, 5-7-membered, 6-7-membered, 6-8-membered, and 6-10-membered rings, etc.

[0096] The term "cycloalkyl" refers to a fully saturated carbon ring that can exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 10-membered ring. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, etc.

[0097] The term "heterocyclic alkyl" refers to a fully saturated cyclic group that may exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3- to 7-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen. Examples of 3-membered heterocyclic alkyl groups include, but are not limited to, ethylene oxide, cyclothioethylene, and cycloazoethylene; non-limiting examples of 4-membered heterocyclic alkyl groups include, but are not limited to, acridine, oxadiazolyl, and thiobutyl; examples of 5-membered heterocyclic alkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, imidazolyl, and tetrahydropyrazolyl; examples of 6-membered heterocyclic alkyl groups include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiaranyl, morpholinyl, piperazine, 1,4-thiaoxane, 1,4-dioxane, thiomorpholinyl, 1,3-dithiaalkyl, and 1,4-dithiaalkyl; and examples of 7-membered heterocyclic alkyl groups include, but are not limited to, azirheptanyl, oxeheptanyl, and thioheptanyl. Monocyclic heterocyclic alkyl groups having 5 or 6 ring atoms are preferred.

[0098] The term "treatment" means administering the compound or preparation described in this application to improve or eliminate a disease or one or more symptoms related to said disease, and includes:

[0099] (i) Suppress the disease or disease state, that is, curb its development;

[0100] (ii) Relieve the disease or disease state, even if the disease or disease state subsides.

[0101] The term “prevention” means administering the compound or formulation described in this application to prevent a disease or one or more symptoms associated with the disease, including: preventing the occurrence of a disease or disease state in mammals, particularly when such mammals are susceptible to the disease state but have not yet been diagnosed with the disease state.

[0102] The word “comprise” or “include” and its English variants such as comprises or comprising should be understood in an open, non-exclusive sense, meaning “including but not limited to”.

[0103] The compounds of this application can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of this application.

[0104] The term "pharmaceutical composition" refers to a mixture of one or more compounds of this application or their salts with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compounds of this application to an organism.

[0105] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0106] The pharmaceutical compositions of this application can be prepared by combining the compounds of this application with suitable pharmaceutically acceptable excipients, for example, in solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalers, gels, microspheres and aerosols.

[0107] Typical routes of administration for the compounds of this application or their pharmaceutically acceptable salts or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0108] The pharmaceutical composition of this application can be manufactured using methods well known in the art, such as conventional mixing, dissolving, granulation, sugar-coated pill making, grinding, emulsification, freeze drying, etc.

[0109] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of this application to be formulated into tablets, pills, lozenges, sugar-coated tablets, capsules, liquids, gels, pastes, suspensions, etc., for oral administration to patients.

[0110] Solid oral compositions can be prepared using conventional mixing, filling, or tableting methods. For example, they can be obtained by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to obtain the core of a tablet or sugar-coated formulation. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, glidants, sweeteners, or flavoring agents.

[0111] The pharmaceutical composition may also be suitable for parenteral administration, such as in suitable unit dosage forms of sterile solutions, suspensions or lyophilized products.

[0112] In all methods of administration of the compounds described herein, the daily dose is from 0.01 to 200 mg / kg body weight, in single or separate doses.

[0113] The compounds of this application can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of this application.

[0114] The structures of the compounds in this application can be confirmed by conventional methods known to those skilled in the art. If this application relates to the absolute configuration of a compound, the absolute configuration can be confirmed by conventional technical means in the art.

[0115] The solvents used in this application are commercially available. The following abbreviations are used in this application: eq represents equivalent amount; DCM represents dichloromethane; PE represents petroleum ether; DMF represents N,N-dimethylformamide; DMSO represents dimethyl sulfoxide; EtOAc or EA represents ethyl acetate; Et represents ethyl; EtOH represents ethanol; MeOH represents methanol; BOC represents tert-butyloxycarbonyl; HOAc represents acetic acid; THF represents tetrahydrofuran; TFA represents trifluoroacetic acid; T S The symbol represents p-toluenesulfonyl; TBS represents tert-butyldimethylsilyl; ADDP represents azodicarbonyldipiperidine; TBAF represents tetrabutylammonium fluoride; TMSI represents trimethyliodosilane; DIEA represents N,N-diisopropylethylamine; HATU represents 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate. Detailed Implementation

[0116] This application has been described in detail through embodiments, but this does not imply any adverse limitations on the application. This document has described the application in detail, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific implementations of this application without departing from the spirit and scope thereof.

[0117] Synthesis of intermediate A

[0118]

[0119] Step 1: Under nitrogen protection at -78°C, a solution of n-butyllithium in n-hexane (2.5M, 427.54mL) was added dropwise to a tetrahydrofuran (2L) solution containing tert-butyldimethyl(2-propynoxy)silane (200g, 1174.24mmol). The reaction mixture was stirred at -78°C for 30 minutes. Then, a tetrahydrofuran (2L) solution of compound A-1 (250g, 971.7mmol) was added dropwise to the reaction mixture at -78°C. The reaction mixture was reacted at -78°C for 3 hours. After the reaction was complete, the reaction mixture was quenched with a saturated aqueous solution of ammonium chloride (2L) and water (1L), extracted with EA (2L*3), and the combined reaction mixture was washed with saturated brine (2L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound A-2. 1 H NMR (400MHz, CDCl3) δ = 5.11 (br d,J=7.3Hz,1H),4.48(s,2H),4.35-4.27(m,1H),4.21(q,J=7.2Hz,2H),2.80-2.59(m,2H),2.30-2.13(m,1H),1.98(br dd,J=6.4,14.2Hz,1H),1.55-1.42(s,9H),1.36-1.27(m,3H),0.93(s,9H),0.19-0.07(s,6H).

[0120] Step 2: Under ice bath conditions, hydrazine hydrate (34.71 g, 1.03 mol, 98%) was added to a 3 L DMF solution containing compound A-2 (400 g, 935.44 mmol). The reaction was carried out at 25 °C for 2 hours. The reaction solution was diluted with water (10 L), extracted with EA (2 L x 2), and the combined reaction solutions were washed with saturated brine (2 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound A-3. MS(ESI)442[M+H + .

[0121] Step 3: Under ice bath conditions, NaBH4 (77.71 g, 2.05 mol) was added in portions to a THF (3 L) solution of compound A-3 (432 g, 978.18 mmol). Then, methanol (0.6 L) was slowly added dropwise. The reaction mixture was stirred at 25 °C for 12 hours until complete. The reaction mixture was quenched with a saturated ammonium chloride aqueous solution (300 mL) under ice bath conditions, then diluted with water (2 L), extracted with EA (2 L * 2), and the combined reaction mixture was washed with saturated brine (2 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound A-4 was obtained by column chromatography (DCM:MeOH). MS (ESI) 400 [M + H) + .

[0122] Step 4: Under ice bath conditions, tributylphosphine (340.24 g, 1.68 mol) was added to tetrahydrofuran (4 L) containing compound A-4 (336 g, 840.84 mmol). The reaction mixture was stirred under ice bath conditions for 30 minutes, and then ADDP (424.31 g, 1.68 mol) was added. The reaction mixture was stirred at 20 °C for 12 hours. The reaction mixture was diluted with water (2 L), extracted with EA (2 L * 2), and the combined reaction mixture was washed with saturated brine (1.5 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound A-5 was obtained by column chromatography (PE:EA). MS (ESI) 382 [M + H] + .

[0123] Step 5: At room temperature, TBAF (1M, 1.02L, 1.02mol) was added to a tetrahydrofuran (1L) solution containing compound A-5 (390g, 1.02mol). The reaction was carried out at 20°C for 1.5 hours. The reaction solution was diluted with water (1L), adjusted to pH 8 with saturated NaHCO3 aqueous solution, extracted with EA (1L*3), and the combined reaction solutions were washed with saturated brine (1L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was then dissolved in ethyl acetate (1L), and HCl / EtOAc (4M, 200mL) was slowly added dropwise to the solution. The mixture was stirred for 1 hour, and a solid was formed. The solid was filtered to obtain compound A-6. MS(ESI) 268[M+H + .

[0124] Step 6: Add manganese dioxide (37.40 g, 430.19 mmol) to a solution of DCM (150 mL) and MeOH (15 mL) containing compound A-6 (11.5 g, 43.02 mmol). Purge the solution three times with nitrogen, then stir at 65 °C for 12 hours. Filter the reaction solution and concentrate to obtain compound A-7. MS(ESI)266[M+H + .

[0125] Step 7: Add NH3·H2O (51.89 g, 414.61 mmol, 57.03 mL, 28% purity) and I2 (31.57 g, 124.38 mmol) to THF (150 mL) containing compound A-7 (11 g, 41.46 mmol). Purge the reaction solution three times with nitrogen, then stir at 25 °C for 12 hours. The reaction is complete. Quench the reaction with saturated sodium sulfite aqueous solution, dilute with 20 mL of water, and extract with ethyl acetate (50 mL * 2). Combine the organic phases, wash with saturated brine (30 mL), dry with sodium sulfate, filter, and concentrate to obtain the crude product. Purify the crude product by column chromatography (PE:EA) to obtain compound A-8. MS (ESI) 263 [M+H + .

[0126] Step 8: At 0°C, TMSI (10.91 g, 54.52 mmol, 7.42 mL) was added to 150 mL of DCM containing compound A-8 (11 g, 41.94 mmol). The reaction solution was stirred at 0°C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain the hydroiodide salt of compound A-9. MS (ESI) determination: 163 [M+H] + .

[0127] Step 9: To a DCM (50 mL) solution of compound A-10 (20 g, 131.08 mmol, 1 eq), p-toluenesulfonyl chloride (27.49 g, 144.19 mmol, 1.1 eq), DMAP (1.6 g, 13.11 mmol, 0.1 eq), and triethylamine (19.9 g, 196.62 mmol, 27.37 mL) were added separately. The resulting solution was stirred at 25 °C for 16 hours until the reaction was complete. The solvent was removed under reduced pressure, and a saturated NaHCO3 solution (50 mL) was added. The mixture was filtered, the filter cake was washed with water, and dried to obtain product A-11. MS(ESI)307[M+H] + .

[0128] Step 10: Add a solution of tetrabutylammonium nitrate (29.78 g, 97.79 mmol, 3 eq) in dichloromethane (50 mL) to a DCM solution of compound A-11 (10 g, 32.60 mmol, 1 eq) at -5 °C, followed by slow addition of trifluoroacetic anhydride (20.54 g, 97.79 mmol, 13.60 mL, 3 eq). Stir the resulting solution at -5 °C for 30 min, then for 16 h until the reaction is complete. Extract with ethyl acetate (500 mL * 3). Wash the combined organic phases successively with water (200 mL * 2) and brine (200 mL * 1). Dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, and recrystallize from dichloromethane to give product A-12. MS(ESI) 352[M+H + .

[0129] Step 11: Add DIEA (26.73 g, 206.82 mmol, 36.0 mL) to isopropanol (200 mL) containing compound A-9 (12 g, 41.36 mmol, hydroiodide) and compound A-12 (11.64 g, 33.09 mmol). Purge the reaction solution three times with nitrogen, then stir at 90 °C for 12 hours. The reaction is complete. Cool the reaction solution, add H₂O (200 mL), filter, and dry to obtain compound A-13. MS (ESI) 478 [M+H] + .

[0130] Step 12: Add Fe (9.36 g, 167.54 mmol) and NH4Cl (12.55 g, 234.56 mmol) to a solution of compound A-13 (16 g, 33.51 mmol) in THF (200 mL) and H2O (50 mL). Purge the solution three times with nitrogen and stir at 100 °C for 1 hour. The reaction is complete. Filter the reaction solution, dilute the filtrate with H2O (100 mL), and extract with ethyl acetate (150 mL * 2). Wash the filter cake with DCM:MeOH (20:1, 100 mL * 3). Combine the extract and washes, dry over sodium sulfate, filter, and concentrate to obtain intermediate A. MS(ESI) 448[M+H + .

[0131] Synthesis of intermediate B

[0132]

[0133] Step 1: Under nitrogen protection at -78°C, a solution of n-butyllithium in n-hexane (2.5M, 85.5mL) was added dropwise to a tetrahydrofuran (500mL) solution containing tert-butyldimethyl(2-propynoxy)silane (38.07g, 223.49mmol, 45.3mL). The reaction mixture was stirred at -78°C for 30 minutes. Then, a tetrahydrofuran (500mL) solution containing compound B-1 (50g, 194.34mmol) was added dropwise to the reaction mixture at -78°C. The reaction mixture was reacted at -78°C for 3 hours. After the reaction was complete, the reaction mixture was quenched with a saturated ammonium chloride aqueous solution (500mL) and water (0.5L), extracted with EA (0.5L*3), and the combined reaction mixture was washed with saturated brine (1L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound B-2.

[0134] Step 2: At 0°C, hydrazine hydrate (7.81 g, 156.01 mmol, 8.81 mL, 95% purity) was added to a DMF (700 mL) solution containing compound B-2 (90 g, 210.47 mmol). The reaction was carried out at 25°C for 2 hours. The reaction solution was diluted with water (1 L), extracted with EA (1 L * 2), and the combined reaction solution was washed with H2O (1 L * 3) and saturated brine (1 L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound B-3. MS(ESI)442[M+H + .

[0135] Step 3: At 0°C, NaBH4 (16.01 g, 423.20 mmol) was added dropwise to a THF (800 mL) solution of compound B-3 (432 g, 978.18 mmol). Then, methanol (200 mL) was slowly added dropwise, and the reaction mixture was stirred at 25°C for 12 hours. The reaction mixture was quenched with a saturated ammonium chloride aqueous solution (300 mL) in an ice bath, then diluted with water (1 L), extracted with EA (1 L * 2), and the combined reaction mixture was washed with saturated brine (1 L), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and subjected to column chromatography (DCM: MeOH) to obtain compound B-4. MS (ESI) 400 [M + H + .

[0136] Step 4: At 0°C, tributylphosphine (68.86 g, 340.34 mmol, 84.0 mL) was added to tetrahydrofuran (1.4 L) containing compound B-4 (68 g, 170.17 mmol). The reaction mixture was stirred at 0°C for 30 minutes, and then ADDP (85.87 g, 340.34 mmol) was added. The reaction mixture was stirred at 20°C for 12 hours. The reaction mixture was filtered, the filtrate was diluted with water (1 L), extracted with EA (1 L * 2), the combined reaction mixture was washed with saturated brine (1.5 L), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and subjected to column chromatography (PE:EA) to obtain compound B-5. MS (ESI) 382 [M + H + .

[0137] Step 5: At room temperature, TBAF (1M, 230.62mL) was added to a tetrahydrofuran (800mL) solution containing compound B-5 (80g, 209.65mmol). The reaction was carried out at 20°C for 0.5 hours. The reaction solution was diluted with water (1L), extracted with EA (1L*2), and the combined reaction solutions were washed with saturated brine (1L), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was dissolved in 800mL EA, 200mL HCl / EA was added, and the mixture was stirred for 1 hour, precipitating 28g of crude product. The crude product was dissolved in 250mL water, the pH was adjusted to 8 with sodium bicarbonate, and then extracted with EA (300mL*2). The organic compounds were combined and concentrated to obtain compound B-6. MS (ESI) 268 [M+H + .

[0138] Step 6: Add manganese dioxide (71.55 g, 822.97 mmol) to a solution of DCM (300 mL) and MeOH (30 mL) containing compound B-6 (22 g, 82.30 mmol, 1 eq). Purge the solution three times with nitrogen, then stir at 60 °C for 12 hours. Filter the reaction solution and concentrate to obtain compound B-7. MS(ESI)266[M+H + .

[0139] Step 7: Add NH3 to 90 mL of THF containing compound B-7 (6 g, 22.62 mmol). .H₂O (28.31 g, 226.15 mmol, 31.11 mL, 28% purity) and I₂ (17.22 g, 67.85 mmol, 13.7 mL) were used. The reaction solution was purged with nitrogen three times, and then stirred at 20 °C for 12 hours. The reaction was complete. A saturated sodium sulfite aqueous solution was added to the reaction solution to quench the reaction, and 10 mL of water was added for dilution. The solution was then extracted with ethyl acetate (15 mL * 2). The organic phases were combined, washed with saturated brine (15 mL), dried over sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (PE:EA) to obtain compound B-8.MS(ESI)₂63[M+H]. + .

[0140] Step 8: At 0°C, TMSI (9.92 g, 49.56 mmol, 6.8 mL) was added to 100 mL of DCM containing compound B-8 (10 g, 38.12 mmol). The reaction solution was stirred at 0°C for 1.5 hours. The reaction was complete. 100 mL of EA was added to the reaction solution, and the mixture was filtered to obtain the hydroiodide salt of compound B-9. MS (ESI) 163 [M+H] + .

[0141] Step 9: Add DIEA (9.36 g, 72.39 mmol, 12.6 mL) to isopropanol (140 mL) containing compound B-9 (7 g, 24.13 mmol, hydroiodide) and 4-chloro-5-nitro-1-(p-toluenesulfonyl)pyrrole[2,3-b]pyridine (8.49 g, 24.13 mmol). Purge the reaction solution three times with nitrogen, then stir at 90 °C for 12 hours. The reaction is complete. Cool the reaction solution, add H₂O (100 mL), and a large amount of solid precipitates. Filter and dry to obtain compound B-10. MS(ESI) 478[M+H] + .

[0142] Step 10: Add Fe powder (8.19 g, 146.60 mmol) and NH4Cl (10.98 g, 205.24 mmol) to a solution of compound B-10 (14 g, 29.32 mmol) in THF (168 mL) and H2O (42 mL), and stir at 90 °C for 1 hour. Filter the reaction solution, dilute the filtrate with H2O (100 mL), and then extract with ethyl acetate (150 mL * 2). Wash the filter cake with DCM:MeOH (20:1, 100 mL * 3). Combine the extract and filtrate, dry over sodium sulfate, filter, and concentrate to obtain intermediate B. MS(ESI) 448[M+H + .

[0143] Example 1: Synthesis of compounds 1A and 1B

[0144]

[0145] Step 1: Intermediate A (500 mg, 1.12 mmol) and 1-1 (174.49 mg, 1.34 mmol) were dissolved in pyridine (10 mL) at 20 °C. 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (321.28 mg, 1.68 mmol) was added, and the mixture was stirred at 20 °C for 4 hours until the reaction was complete. 5 mL of ethyl acetate was added to the reaction mixture, and the mixture was washed with water (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product 1-2. MS ESI 560 [M+H] + .

[0146] Step 2: Compounds 1-2 (360 mg, 643.27 μmol) were dissolved in acetic acid (5 mL), purged three times with nitrogen, and then heated to 100 °C. The mixture was stirred for 16 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure, then diluted with 20 mL of ethyl acetate, washed with saturated sodium bicarbonate aqueous solution (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate) to obtain compounds 1-3. MS ESI 542 [M+H] + .

[0147] Step 3: To a solution of 1-3 (260 mg, 480.04 μmol) in tetrahydrofuran (4 mL), add tetrabutylammonium fluoride (1 M in THF, 960.08 μmol), then heat to 66 °C and stir for 16 hours. Concentrate the reaction solution under reduced pressure, then dilute with 10 mL of ethyl acetate, wash with water (10 mL × 3), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain the crude product. The crude product is then preparatively separated by high-performance liquid chromatography (HPLC) (column: Waters Xbridge 150*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 20%-50%, 10 min) to obtain compound 1A, retention time: 5.438 min. MS ESI 388 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ=12.01-11.74(m,1H),8.58(s,1H),7.42(d,J=3.4Hz,1H),6.97-6.85(m,1H),6.35-6.09(m,1H ),5.26-5.10(m,1H),5.09-4.90(m,1H),4.74(s,2H),4.08-3.92(m,1H),3.24-3.13(m,1H),3.11-2.98(m,1H),2.55(br d,J=12.3Hz,4H),2.46-2.40(m,1H),2.24-2.08(m,1H),1.27(s,3H)

[0148] Compound 1B, retention time: 6.366 min, MS ESI 388 [M+H] + .

[0149] 1 H NMR (400MHz, DMSO-d6) δ = 12.03-11.81 (m, 1H), 8.56 (s, 1H), 7.42 (br s,1H),6.91(s,1H),6.36-6.16(m,1H),5.41-5.20(m,1H),5.12(s,1H),4.69(br d,J=8.9Hz,2H),3.62-3.47(m,1H),3.24-3.14(m,1H),3.12-3.00(m,1H ),2.73-2.55(m,3H),2.45-2.37(m,2H),2.18-2.06(m,1H),1.38(s,3H).

[0150] Example 2: Synthesis of compounds 2A and 2B

[0151]

[0152] Step 1: Intermediate A (100 mg, 223.46 μmol) and 2-1 (32.27 mg, 290.50 μmol) were dissolved in pyridine (1 mL). 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (64.26 mg, 335.19 μmol) was added, and the mixture was stirred at 25 °C for 16 hours until complete. 5 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with water (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was then separated by preparative chromatography (PE:EA) to obtain compound 2-2. MS ESI 541 [M+H] + .

[0153] Step 2: Compound 2-2 (100 mg, 184.98 μmol) was dissolved in acetic acid (2 mL), purged three times with nitrogen, and then heated to 100 °C. The mixture was stirred for 16 hours under nitrogen protection. The reaction solution was diluted with 10 mL of ethyl acetate, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated sodium bicarbonate aqueous solution (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative chromatography (PE:EA) to obtain compound 2-3. MS ESI 523 [M+H] + .

[0154] Step 3: To a solution of 2-3 (60 mg, 114.81 μmol) in tetrahydrofuran (2 mL), add tetrabutylammonium fluoride (1 M HF solution, 574.07 μmol), then heat to 25 °C and stir for 16 hours. After the reaction is complete, dilute the reaction solution with 10 mL of water, extract with ethyl acetate (10 mL × 3), combine the organic phases, wash with brine (20 mL × 3), dry with anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain the crude product. The crude product is then separated by high performance liquid chromatography (HPLC) (column: Phenomenex Gemini-NX C18 75*30 mm*3 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 20%-50%, 7 min) to obtain compounds 2-4. MS ESI 369 [M+H] + .

[0155] Step 4: Compounds 2-4 (30 mg, 81.43 μmol) were separated by SFC (column: DAICL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH3H2O ​​IPA]; B%: 45%-45%, 4.2 min) to obtain compound 2A, retention time: 1.888 min, MS ESI 369 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ=11.95(br s,1H),8.52(s,1H),7.45(t,J=3.0Hz,1H),6.92(s,1H),6.61-6.31(m,1H),5.74-5.58(m,1H),4.98-4.82 (m,1H),4.79-4.65(m,1H),3.44(s,1H),3.27-3.18(m,1H),3.17-3.06(m,1H),2.85-2.69(m,1H),2.48(br d, J = 3.0 Hz, 1H), 2.36–2.29 (m, 1H), 1.75 (t, J = 7.5 Hz, 2H) Compound 2B, retention time: 2.325 min, MS ESI 369 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ=11.95(br s,1H),8.53(s,1H),7.45(t,J=2.9Hz,1H),6.92(s,1H),6.63-6.34(m,1H),5.74-5.52(m,1H),4.82(s,2H),3.45(br s,1H),3.29-3.18(m,1H),3.13-3.00(m,1H),2.86-2.69(m,1H),2.48-2.44(m,1H),2.41-2.34(m,1H),1.74(br t,J=7.5Hz,2H).

[0156] Example 3: Synthesis of compounds 3A and 3B

[0157]

[0158] Step 1: Intermediate B (100 mg, 223.46 μmol) and 2-1 (32.27 mg, 290.50 μmol) were dissolved in pyridine (1 mL). 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (64.26 mg, 335.19 μmol) was added, and the mixture was stirred at 25 °C for 16 hours until complete. 5 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with water (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was then separated by preparative chromatography (PE:EA) to obtain compound 3-1. MS ESI 541 [M+H] + .

[0159] Step 2: Compound 3-1 (90 mg, 166.48 μmol) was dissolved in acetic acid (2 mL), purged three times with nitrogen, and then heated to 100 °C. The mixture was stirred for 16 hours under nitrogen protection. The reaction solution was diluted with 10 mL of ethyl acetate, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with ethyl acetate (10 mL × 3), and the combined organic phases were washed with saturated sodium bicarbonate aqueous solution (10 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative chromatography (PE:EA) to obtain compound 3-2. MS ESI 523 [M+H] + .

[0160] Step 3: To a 2 mL solution of tetrahydrofuran containing 60 mg (114.81 μmol) of 3-2, add a tetrabutylammonium fluoride (1 mol / L, 574.07 μmol) solution of tetrahydrofuran, then heat to 25 °C and stir for 16 hours. Dilute the reaction solution with 10 mL of water, extract with ethyl acetate (10 mL × 3), combine the organic phases and wash with brine (20 mL × 3), dry with anhydrous sodium sulfate, filter and concentrate under reduced pressure to obtain the crude product. The crude product is then separated by high performance liquid chromatography (HPLC) (column: Phenomenex Gemini-NXC18 75*30 mm*3 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 20%-50%, 7 min) to obtain compound 3-3, MS ESI 369 [M+H]. + .

[0161] Step 4: 3-3 (30 mg, 81.43 μmol) was separated by SFC (column: DAICL CHIRALPAK IC (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH3H2O ​​ETOH]; B%: 60%-60%; 30 min) to obtain compound 3A, retention time: 1.155 min, MS ESI 369 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ=11.95(br s,1H),8.52(s,1H),7.45(t,J=2.9Hz,1H),6.91(s,1H),6.60-6.34(m,1H),5.74-5.50(m,1H),4.89-4.62(m,2H),3.44(br dd,J=2.3,6.0Hz,1H),3.22(br s,1H),3.12-3.00(m,1H),2.85-2.69(m,1H),2.46(br s,1H),2.42-2.33(m,1H),1.74(t,J=7.6Hz,2H)

[0162] Compound 3B, retention time: 2.092 min, MS ESI 369 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ=11.95(br s,1H),8.52(s,1H),7.45(t,J=3.0Hz,1H),6.92(s,1H),6.62-6.33(m,1H),5.80-5.56(m,1H),4.94-4.83(m,1H),4.75(s,1H),3.44(br d,J=4.4Hz,1H),3.27-3.17(m,1H),3.17-3.06(m,1H),2.86-2.70(m,1H),2.48-2.43(m,1H),2.37-2.29(m,1H),1.75(t,J=7.5Hz,2H).

[0163] Example 4: Synthesis of Compound 4

[0164]

[0165] Step 1: Intermediate B (61.19 mg, 136.73 μmol) and 4-1 (200 mg, 175 μmol) were dissolved in DMF (5 mL) at 25 °C. HATU (220.91 mg, 580.99 μmol) and DIEA (115.52 mg, 893.83 μmol, 155.69 μL) were added, and the reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by rapid silica gel column chromatography to obtain 4-2. MS ESI 544 [M+H] + .

[0166] Step 2: Compound 4-2 (250 mg, 459.90 μmol) was dissolved in HOAc (5 mL). The reaction solution was heated to 120 °C and stirred for 2 hours. The reaction was complete. The reaction solution was concentrated under reduced pressure. The crude product was adjusted to pH 8-9 with saturated sodium bicarbonate solution and extracted with DCM (50 mL * 2). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product 4-3. MS ESI 526 [M+H] + .

[0167] Step 3: At 0°C, compound 4-3 (200 mg, 380.53 μmol) was dissolved in THF (8 mL) and MeOH (2 mL) solutions, and NaBH4 (28.79 mg, 761.06 μmol) was added. The reaction solution was stirred at 25°C for 12 hours. The reaction solution was quenched at 0°C with saturated ammonium chloride solution (50 mL * 2), diluted with water (20 mL), and extracted with DCM (50 mL * 2). The combined organic phases were concentrated under reduced pressure to obtain crude product 4-4. MS ESI 528 [M + H] + .

[0168] Step 4: To a tetrahydrofuran (5 mL) solution of compound 4-4 (180 mg, 341.17 μmol), tetrabutylammonium fluoride (1 M THF solution, 682.34 μL) was added, and the mixture was heated to 75 °C and stirred for 12 hours. The reaction solution was concentrated under reduced pressure, washed with saturated sodium bicarbonate (15 mL), and extracted with DCM (10 mL × 3). The combined organic phases were concentrated under reduced pressure to obtain the crude product. The crude product was subjected to Prep-HPLC (TFA condition) (column: Welch Ultimate C18 100*40 mm*3 μm; mobile phase: [H2O (0.075% TFA)-ACN]; B%: 20%-50%, 8 min) to obtain compound 4, MS ESI 374 [M+H]. + .

[0169] 1 H NMR (400MHz, DMSO-d6)δ=11.97(br s,1H),8.63(s,1H),7.45(br s,1H),6.91(s,1H),6.32(br s,1H),5.65(br d,J=9.5Hz,1H),4.80-4.68(m,2H),4.37(br d,J=8.3Hz,1H),3.05(br d,J=11.5Hz,2H),2.80-2.70(m,1H),2.36-2.19(m,2H),1.62(br s,1H),0.68-0.48(m,3H),0.39-0.28(m,1H).

[0170] Example 5: Synthesis of Compound 5

[0171]

[0172] Step 1: Dissolve intermediate B (500.00 mg, 1.12 mmol) in AcOH (5 mL), and heat the reaction solution to 120 °C with stirring for 2 hours. Concentrate the reaction solution under reduced pressure to obtain the crude product. Dilute the crude product with water (50 mL), extract with DCM (50 mL * 3), and concentrate the combined organic phases under reduced pressure to obtain crude product 5-1. MS ESI 472 [M + H] + .

[0173] Step 2: Compound 5-1 (460 mg, 975.54 μmol) was dissolved in 1,4-dioxane (10 mL), and SeO2 (162.37 mg, 1.46 mmol) was added. The reaction mixture was heated to 110 °C and stirred for 16 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was diluted with water (50 mL), extracted with EA (50 mL * 2), and the combined organic phases were concentrated under reduced pressure to obtain the crude product. The crude product was purified by rapid silica gel column chromatography to obtain 5-2. MS ESI 486 [M + H] + .

[0174] Step 3: Dissolve 5-2 (160 mg, 329.55 μmol) in DCM (10 mL), add 5-3 (132.73 mg, 659.09 μmol), and stir the reaction solution at 25 °C for 12 hours. Then add NaBH(OAc)3 (139.69 mg, 659.09 μmol), and stir the reaction solution at 25 °C for another 12 hours. Dilute the reaction solution with water (50 mL), extract with DCM (50 mL * 2), wash the combined organic phases with saturated brine (30 mL), dry to anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain crude 5-4. MS ESI 672 [M + H] + .

[0175] Step 4: To a tetrahydrofuran solution of 5-4 (110 mg, 163.96 μmol), add a tetrabutylammonium fluoride solution of 1 mol / L (491.88 μL) in tetrahydrofuran, then heat to 75 °C and stir for 12 hours. After the reaction is complete, concentrate the reaction solution under reduced pressure, wash with saturated sodium bicarbonate (30 mL), extract with DCM (50 mL × 2), and concentrate the combined organic phases under reduced pressure to obtain the crude product. The crude product is then subjected to Prep-HPLC (basic conditions) (column: Phenomenex Gemini-NX80*40 mm*3 μm; mobile phase: [H2O (0.05% NH3H2O)-ACN]; B%: 16%-46%, 8 min) to obtain compound 5. MS ESI 403 [M+H] + .

[0176] 1H NMR (400MHz, DMSO-d6)δ=11.94(br s,1H),8.57(s,1H),7.45(br s,1H),6.91(s,1H),6.36(br s,1H),5.67-5.52(m,1H),5.25(s,1H),4.74(br d,J=8.5Hz,2H),4.08(d,J=13.1Hz,1H),3.93(br d,J=13.1Hz,1H),3.21(br d,J=4.3Hz,2H),3.11(br d,J=6.3Hz,1H),3.00(br t,J=7.0Hz,3H),2.69(br dd,J=4.6,12.4Hz,1H),2.25(br s,1H),1.32(s,3H).

[0177] Bioactivity test

[0178] Experimental Example 1: In vitro activity assay of Jak1, Jak2, Jak3, and Tyk2 kinases

[0179] Experimental materials

[0180] Recombinant human JAK1, JAK2, JAK3, Tyk2 proteases, major instruments, and reagents were all provided by Eurofins, a UK-based company.

[0181] Experimental methods

[0182] JAK2, JAK3, and TYK2 dilutions: 20 mM 3-(N-morpholine)propanesulfonic acid (MOPS), 1 mM EDTA, 0.01% Brij-35.5% glycerol, 0.1% β-mercaptoethanol, 1 mg / mL BSA; JAK1 dilution: 20 mM TRIS, 0.2 mM EDTA, 0.1% β-mercaptoethanol, 0.01% Brij-35.5% glycerol. All compounds were prepared into 100% DMSO solutions, reaching a final assay concentration 50-fold. The test compounds were serially diluted 3-fold to nine concentrations, from 10 μM to 0.001 μM, with DMSO comprising 2% of the assay reaction. The working stock solution of the compound was added as the first component of the reaction to the assay well, followed by the addition of the remaining components according to the assay details below.

[0183] JAK1(h) enzyme reaction

[0184] JAK1(h) with 20 mM Tris / HCl pH 7.5, 0.2 mM EDTA, 500 μM MGEEPLYWSFPAKKK, 10 mM magnesium acetate and [γ- 33Incubate together with Mg / ATP (adjust activity and concentration as needed). Initiate the reaction by adding the Mg / ATP mixture, incubate at room temperature for 40 minutes, then terminate the reaction by adding 0.5% phosphate. Then spot 10 μL of the reaction mixture onto a P30 filter pad and wash three times with 0.425% phosphate and once with methanol over 4 minutes, dry, and perform scintillation counting.

[0185] JAK2(h) enzyme reaction

[0186] JAK2(h) with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 100 μM MTTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC, 10 mM magnesium acetate and [γ- 33 Incubate together with Mg / ATP (adjust activity and concentration as needed). Initiate the reaction by adding the Mg / ATP mixture, incubate at room temperature for 40 minutes, then terminate the reaction by adding 0.5% phosphate. Then spot 10 μL of the reaction mixture onto a P30 filter pad and wash three times with 0.425% phosphate and once with methanol over 4 minutes, dry, and perform scintillation counting.

[0187] Data Analysis

[0188] IC 50 The results were obtained by analyzing IDBS's XLFIT5 (Formula 205), as detailed in Table 1.

[0189] Table 1. Results of in vitro screening tests of compounds in this application

[0190]

[0191] Conclusion: The compounds of this application exhibited good selective inhibition of JAK1 and / or JAK2 in in vitro kinase activity assays.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, , in, m is 1; n is 1, 2, 3 or 4; Ring A is selected from cyclopropyl, cyclobutyl, or heterocyclobutane; each R is independently selected from H, F, Cl, Br, I, OH, NH2, CN, or C1-C6alkyl; 1 each R is independently selected from H, F, Cl, Br, I, OH, NH2, CN, or C1-C6alkyl; 1-3 alkyl; Each R 2 Each was independently selected from CN; L represents a bond or -CH2-.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, n is 1, 2, or 3.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, n is 1 or 2.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, n is 1.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, each R is independently selected from H, OH, CN, or C 1 are each independently selected from H, OH, CN, or C 1-3 alkyl.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, Each R 1 Each is independently selected from H, OH, CN, or methyl.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, The compound of formula (I) or a pharmaceutically acceptable salt thereof is a compound of formula (I-1) or a compound of formula (I-2) or a pharmaceutically acceptable salt thereof: in, m is 1; n is 1, 2, 3 or 4; Ring A is selected from cyclopropyl, cyclobutyl, or heterocyclobutane; each R is independently selected from H, F, Cl, Br, I, OH, NH2, CN, or C1-C6alkyl; 1 each R is independently selected from H, F, Cl, Br, I, OH, NH2, CN, or C1-C6alkyl; 1-3 alkyl; Each R 2 Each was independently selected from CN; L represents a bond or -CH2-.

8. The following compounds or their pharmaceutically acceptable salts, or .

9. The following compounds or their pharmaceutically acceptable salts: or .

10. The use of the compound of any one of claims 1-9 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing JAK-related diseases, wherein the JAK-related diseases are selected from inflammatory conditions.

Citation Information

Patent Citations

  • Tricyclic heterocyclic compounds, compositions and methods of use thereof

    CN102712640A